Reseñas

R. MEDINA ; J. L. LINARES y M. R. CEBERIO, La Terapia Familiar desde Iberoaméric

Artistas sobre outras Obras

A inovação integra a manifestação artística de um modo que parece ser-lhe essencial. É uma renovação constante, de dentro para fora, reconstrói-se e restrutura-se quase em permanência, interrogando paradigmas. As novas formulações as próprias categorias e géneros são reformulados em permanência, reorganizados e reconstruídos. A complexidade adensa-se com as estruturas organizadas de salvaguarda, de acervo e de disseminação, partilhando-se a autoria em direção a um coletivo cultural e civilizacional. Os artigos reunidos neste número 36 da Revista Estúdio propõem uma abordagem entre pares: são, como aqui é apanágio, os próprios artistas que escolheram e analisaram as obras dos seus companheiros de profissão que aqui são apresentadosinfo:eu-repo/semantics/publishedVersio

Artistas sobre outras obras

Este número da Revista Estúdio assinala a crescente maturação de um espaço de comunicação algo alternativo, onde artistas falam de artistas, dão a conhecer obras menos conhecidas, e ocupam uma área de curadoria expontânea e paralela aos centros do arte world. Dá-se a palavra aos próprios criadores, e há seis anos que o seu olhar vem enriquecendo um património crescente, com especiais ligações aos países onde se fala as línguas ibéricas. A presença de obras de Portugal, Espanha, Brasil, Angola, Argentina, Perú, Venezuela, Bolívia e muitos outros países tornou-se habitual, fazendo da Estúdio uma instância da semiosfera (Lotman). Mais do que a presença, é a dimensão do conhecimento transmitido, a que se segue, naturalmente, o estabelecimento de novas teias de referência entre os artistas destes países: há novos grupos, novas cumplicidades, novas realizações dentro deste Estúdio, que completa seis anos de publicação persistente. A Revista Estúdio é também mais uma via disponível para o exercício da interpretação, através de descodificações mais informadas, mais negociadas, dos textos artísticos, pois são efectuadas por outros artistas. Reuniram-se nesta edição 24 artigos originais, mantendo a sua linha editorial inicial. O projecto mantém a sua componente de resistência, de plataforma de conhecimento para os pares, não abdicando também da validação externa, ou seja, do uso de protocolos de produção e transmissão de conhecimento. Falamos pois das normas de redação, de referenciação, de estruturação de textos e de articulação de argumentos, visuais ou verbais. Estabelece-se neste volume uma articulação entre cinema, vídeo, redes, escultura, instalação, fotografia, performance, banda desenhada, pintura, cerâmica, poesia concreta, livros de artista, sendo este conjunto não exaustivo testemunha do grau de hibridação que hoje o discurso artístico convoca. Apanhando-lhe o pulso, a Estúdio acompanha a arte desde os seus produtores, dos seus procedimentos, dos seus recursos, dos seus resultados. A Estúdio permite visitar muitos estúdios.info:eu-repo/semantics/publishedVersio

Reseñas

R. MEDINA ; J. L. LINARES y M. R. CEBERIO, La Terapia Familiar desde Iberoaméric

Immune-Related Adverse Events and Corticosteroid Use for Cancer-Related Symptoms Are Associated With Efficacy in Patients With Non-small Cell Lung Cancer Receiving Anti-PD-(L)1 Blockade Agents

Background: Immune-related adverse events (irAEs) have been associated with improved efficacy in advanced non-small cell lung cancer (NSCLC) patients receiving anti-PD-(L)1 blockade agents, while the concurrent use of corticosteroids seems to worsen it. We evaluated outcomes in advanced NSCLC patients treated with anti-PD-(L)1 blockade agents in relation to the presence of irAEs and the reasons for using corticosteroids: whether for palliative cancer-related reasons or for the management of irAEs. Methods: Clinical outcomes in advanced NSCLC patients treated with anti-PD-(L)1 blockade agents were calculated with regard to the presence of irAEs and the use of corticosteroids. A landmark analysis was performed to avoid immortal time bias due to the time-dependent nature of irAEs. Results: Out of a total of 267 patients, the 56.9% of patients who experienced irAEs had significantly improved outcomes. In the landmark analysis, median progression-free survival (PFS) was 12.4 months for patients with irAEs vs. 4.1 months for patients without irAEs (p < 0.001), while median overall survival (OS) was 28.2 vs. 12.5 months, respectively (p < 0.001). Likewise, objective response and disease control rates were significantly higher in patients experiencing irAEs: 48.6 vs. 22.8% and 77.1 vs. 39.6% (p < 0.001), respectively. Median OS was significantly shorter for patients receiving ≥10 mg of prednisone equivalent daily for cancer-related symptoms than for the rest of patients (<10 mg prednisone equivalent daily or for management of irAEs): 6 vs. 15.9 months (p < 0.001). Conclusions: IrAEs were associated with improved efficacy in advanced NSCLC patients when a landmark analysis was applied. Patients receiving corticosteroids had significantly poorer outcomes when they were used for cancer-related symptoms

Neurocysticercosis: relationship between Taenia antigen levels in CSF and MRI Neurocisticercose: relação entre antígeno da Taenia no líquido cefalorraquidiano e ressonância magnética

OBJECTIVE: To determine the relationship between Taenia antigen (TA) detection in cerebrospinal fluid (CSF) and magnetic resonance imaging (MRI) findings in patients with definite diagnosis of neurocysticercosis (NC). METHOD: Sixty-three patients with definite diagnosis of NC were submitted to a MRI of the brain, and to a CSF examination, with a meticulous search for TA by ELISA. RESULTS: TA detection was positive in 36 patients (57.1%). A total of 836 lesions were analyzed, greatly within the cerebral parenchyma (98.7 of the lesions). Intact or non-degenerating cysts were the most common evolutive phase observed (50.4% of all lesions), 22.1% were degenerating cysts and 19.5% calcified cysts. We observed a significant relationship between TA levels detected and the total number of lesions and the number of non-degenerating cysts, but not with calcified lesions. CONCLUSION: According to our results, we propose at least four important types of contribution: (1) TA detection may allow etiologic diagnosis in transitional phases of NC, with non-characteristic images; (2) in final stages of evolution of cysticercoids in the CNS, lesions may not appear on CT or MRI, and TA detection may contribute to a definite etiologic diagnosis; (3) TA detection may permit diagnosis of NC in some patients with previous negative tests for antibody detection in CSF; (4) TA detection may represent an accurate marker of disease activity in the epileptic form of NC.<br>OBJETIVO: Determinar a relação entre a detecção de antígeno de Taenia (TA) no líquido cefalorraquidiano (LCR) e achados de ressonância magnética (RM) em pacientes com diagnóstico definitivo de neurocisticersose. MÉTODO: Sessenta e três pacientes com diagnóstico de NC foram submetidos a exame de RM e exame de LCR com pesquisa de antígeno de Taenia por método imunoenzimático. RESULTADOS: A detecção de TA foi positiva em 36 pacientes (57,1%). Um total de 836 lesões foram analizadas sendo 98,7% intraparemquimatosas, 50,4% dos cistos encontravam-se íntegros, 22,1% degenerados e 19,5% calcificados. Foi observada relação significativa entre a presença dos níveis de TA detectados com o número total dos cistos e também com o número de cistos íntegros. Não foi observada relação com cistos calcificados. CONCLUSÃO: (1) a detecção de TA permite o diagnóstico etiológico em formas transicionais na NC com imagem pouco característica; (2) em estágio evolutivo final de um cisticerco no sistema nervoso, este pode não aparecer na tomografia computadorizada ou RM sendo a presença do antígeno importante para confirmação diagnóstica; (3) a detecção do TA permite também o diagnóstico de NC nos casos em que as reações inumológicas são negativas; (4) a detecção do TA representa um marcador de atividade da doença nas formas epiléticas da NC

Correction to: Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry

International audienceIn this article, the name of the GLORIA-AF investigator Anastasios Kollias was given incorrectly as Athanasios Kollias in the Acknowledgements. The original article has been corrected

Patterns of oral anticoagulant use and outcomes in Asian patients with atrial fibrillation: a post-hoc analysis from the GLORIA-AF Registry

Background: Previous studies suggested potential ethnic differences in the management and outcomes of atrial fibrillation (AF). We aim to analyse oral anticoagulant (OAC) prescription, discontinuation, and risk of adverse outcomes in Asian patients with AF, using data from a global prospective cohort study. Methods: From the GLORIA-AF Registry Phase II-III (November 2011-December 2014 for Phase II, and January 2014-December 2016 for Phase III), we analysed patients according to their self-reported ethnicity (Asian vs. non-Asian), as well as according to Asian subgroups (Chinese, Japanese, Korean and other Asian). Logistic regression was used to analyse OAC prescription, while the risk of OAC discontinuation and adverse outcomes were analysed through Cox-regression model. Our primary outcome was the composite of all-cause death and major adverse cardiovascular events (MACE). The original studies were registered with ClinicalTrials.gov, NCT01468701, NCT01671007, and NCT01937377. Findings: 34,421 patients were included (70.0&nbsp;±&nbsp;10.5 years, 45.1% females, 6900 (20.0%) Asian: 3829 (55.5%) Chinese, 814 (11.8%) Japanese, 1964 (28.5%) Korean and 293 (4.2%) other Asian). Most of the Asian patients were recruited in Asia (n&nbsp;=&nbsp;6701, 97.1%), while non-Asian patients were mainly recruited in Europe (n&nbsp;=&nbsp;15,449, 56.1%) and North America (n&nbsp;=&nbsp;8378, 30.4%). Compared to non-Asian individuals, prescription of OAC and non-vitamin K antagonist oral anticoagulant (NOAC) was lower in Asian patients (Odds Ratio [OR] and 95% Confidence Intervals (CI): 0.23 [0.22-0.25] and 0.66 [0.61-0.71], respectively), but higher in the Japanese subgroup. Asian ethnicity was also associated with higher risk of OAC discontinuation (Hazard Ratio [HR] and [95% CI]: 1.79 [1.67-1.92]), and lower risk of the primary composite outcome (HR [95% CI]: 0.86 [0.76-0.96]). Among the exploratory secondary outcomes, Asian ethnicity was associated with higher risks of thromboembolism and intracranial haemorrhage, and lower risk of major bleeding. Interpretation: Our results showed that Asian patients with AF showed suboptimal thromboembolic risk management and a specific risk profile of adverse outcomes; these differences may also reflect differences in country-specific factors. Ensuring integrated and appropriate treatment of these patients is crucial to improve their prognosis. Funding: The GLORIA-AF Registry was funded by Boehringer Ingelheim GmbH

Weaning from mechanical ventilation in intensive care units across 50 countries (WEAN SAFE): a multicentre, prospective, observational cohort study

International audienceBackground: Current management practices and outcomes in weaning from invasive mechanical ventilation are poorly understood. We aimed to describe the epidemiology, management, timings, risk for failure, and outcomes of weaning in patients requiring at least 2 days of invasive mechanical ventilation. Methods: WEAN SAFE was an international, multicentre, prospective, observational cohort study done in 481 intensive care units in 50 countries. Eligible participants were older than 16 years, admitted to a participating intensive care unit, and receiving mechanical ventilation for 2 calendar days or longer. We defined weaning initiation as the first attempt to separate a patient from the ventilator, successful weaning as no reintubation or death within 7 days of extubation, and weaning eligibility criteria based on positive end-expiratory pressure, fractional concentration of oxygen in inspired air, and vasopressors. The primary outcome was the proportion of patients successfully weaned at 90 days. Key secondary outcomes included weaning duration, timing of weaning events, factors associated with weaning delay and weaning failure, and hospital outcomes. This study is registered with ClinicalTrials.gov, NCT03255109. Findings: Between Oct 4, 2017, and June 25, 2018, 10 232 patients were screened for eligibility, of whom 5869 were enrolled. 4523 (77·1%) patients underwent at least one separation attempt and 3817 (65·0%) patients were successfully weaned from ventilation at day 90. 237 (4·0%) patients were transferred before any separation attempt, 153 (2·6%) were transferred after at least one separation attempt and not successfully weaned, and 1662 (28·3%) died while invasively ventilated. The median time from fulfilling weaning eligibility criteria to first separation attempt was 1 day (IQR 0–4), and 1013 (22·4%) patients had a delay in initiating first separation of 5 or more days. Of the 4523 (77·1%) patients with separation attempts, 2927 (64·7%) had a short wean (≤1 day), 457 (10·1%) had intermediate weaning (2–6 days), 433 (9·6%) required prolonged weaning (≥7 days), and 706 (15·6%) had weaning failure. Higher sedation scores were independently associated with delayed initiation of weaning. Delayed initiation of weaning and higher sedation scores were independently associated with weaning failure. 1742 (31·8%) of 5479 patients died in the intensive care unit and 2095 (38·3%) of 5465 patients died in hospital. Interpretation: In critically ill patients receiving at least 2 days of invasive mechanical ventilation, only 65% were weaned at 90 days. A better understanding of factors that delay the weaning process, such as delays in weaning initiation or excessive sedation levels, might improve weaning success rates. Funding: European Society of Intensive Care Medicine, European Respiratory Society